NanoBio inks $54.5M development deal with GSK

Ann Arbor, MI-based NanoBio has inked a deal with GlaxoSmithKline for an experimental cold sore therapy poised to go into late-stage testing. NanoBio picks up a $14.5 million upfront payment and stands to earn up to $40 million in milestones and single digit royalties on any marketed therapy. "GSK's demonstrated leadership in developing and marketing consumer healthcare products, including the leading product for the treatment of herpes labialis, makes them the ideal partner for NB-001," NanoBio CEO James Baker says in a statement. Release 

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.